Propionic Acidemia Just Got Pharma's Attention

Moderna and Recordati join forces on mRNA-3927, targeting propionic acidemia with a $160M+ deal covering clinical and commercial rights

16 Jun 2026

Moderna has found its commercial partner for one of its most ambitious bets outside vaccines. On January 29, the company announced a collaboration with Italian pharmaceutical firm Recordati to carry mRNA-3927, an investigational treatment for propionic acidemia, through final clinical development and into global markets. Recordati will pay $50 million upfront, with up to $110 million in near-term milestones, plus tiered royalties tied to future sales. Moderna keeps full control of development and manufacturing throughout.

Propionic acidemia is both rare and unforgiving. Caused by an enzyme deficiency, the genetic disorder prevents patients from processing certain proteins and fats normally, leaving them vulnerable to metabolic crises that can turn fatal without careful management. Few effective treatment options exist, which is precisely why mRNA-3927 has drawn attention far beyond the patient community it targets.

What makes this deal worth watching isn't just the dollar figures. Chronic genetic diseases demand something fundamentally different from mRNA technology: not a single protective dose, but sustained, repeated administration across years. Pulling that off would prove mRNA is a durable platform for inherited metabolic conditions, not just a vehicle for fighting infectious disease. That's the shift Moderna is quietly staking its next chapter on.

Recordati steps in as the commercial engine once approval arrives, drawing on its existing rare-disease infrastructure across major markets. Each company plays to its strengths, Moderna driving science and supply while Recordati navigates the commercialization side. Analysts tracking the broader industry know what's riding on this: Pfizer and Moderna already rewrote the commercial playbook for infectious disease.

Whether mRNA can do the same in rare disease remains the open question, and forward progress on mRNA-3927 may be the clearest early answer the market gets.